Sharps Compliance Corp.

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, WM has a market cap of 93.3B. Regarding current trading prices, SMED is priced at $8.75, while WM trades at $233.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas WM's P/E ratio is 34.46. In terms of profitability, SMED's ROE is +0.34%, compared to WM's ROE of +0.29%. Regarding short-term risk, SMED is less volatile compared to WM. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check WM's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, RSG has a market cap of 67.9B. Regarding current trading prices, SMED is priced at $8.75, while RSG trades at $223.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas RSG's P/E ratio is 32.01. In terms of profitability, SMED's ROE is +0.34%, compared to RSG's ROE of +0.18%. Regarding short-term risk, SMED is less volatile compared to RSG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check RSG's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, WCN has a market cap of 41.6B. Regarding current trading prices, SMED is priced at $8.75, while WCN trades at $164.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas WCN's P/E ratio is 38.92. In terms of profitability, SMED's ROE is +0.34%, compared to WCN's ROE of +0.13%. Regarding short-term risk, SMED is less volatile compared to WCN. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check WCN's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, GFLU has a market cap of 25B. Regarding current trading prices, SMED is priced at $8.75, while GFLU trades at $70.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas GFLU's P/E ratio is -91.90. In terms of profitability, SMED's ROE is +0.34%, compared to GFLU's ROE of N/A. Regarding short-term risk, SMED is less volatile compared to GFLU. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GFLU's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, CLH has a market cap of 14.7B. Regarding current trading prices, SMED is priced at $8.75, while CLH trades at $289.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas CLH's P/E ratio is 37.84. In terms of profitability, SMED's ROE is +0.34%, compared to CLH's ROE of +0.14%. Regarding short-term risk, SMED is less volatile compared to CLH. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CLH's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, GFL has a market cap of 14.1B. Regarding current trading prices, SMED is priced at $8.75, while GFL trades at $42.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas GFL's P/E ratio is 99.34. In terms of profitability, SMED's ROE is +0.34%, compared to GFL's ROE of +0.50%. Regarding short-term risk, SMED is less volatile compared to GFL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GFL's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, SRCL has a market cap of 5.8B. Regarding current trading prices, SMED is priced at $8.75, while SRCL trades at $61.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas SRCL's P/E ratio is 158.92. In terms of profitability, SMED's ROE is +0.34%, compared to SRCL's ROE of -0.01%. Regarding short-term risk, SMED is more volatile compared to SRCL. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check SRCL's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, CWST has a market cap of 4.9B. Regarding current trading prices, SMED is priced at $8.75, while CWST trades at $84.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas CWST's P/E ratio is 646.67. In terms of profitability, SMED's ROE is +0.34%, compared to CWST's ROE of +0.01%. Regarding short-term risk, SMED is less volatile compared to CWST. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CWST's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, NVRI has a market cap of 1.5B. Regarding current trading prices, SMED is priced at $8.75, while NVRI trades at $18.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas NVRI's P/E ratio is -8.91. In terms of profitability, SMED's ROE is +0.34%, compared to NVRI's ROE of -0.49%. Regarding short-term risk, SMED is less volatile compared to NVRI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check NVRI's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, HCCI has a market cap of 1.1B. Regarding current trading prices, SMED is priced at $8.75, while HCCI trades at $45.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas HCCI's P/E ratio is 14.22. In terms of profitability, SMED's ROE is +0.34%, compared to HCCI's ROE of +0.22%. Regarding short-term risk, SMED is more volatile compared to HCCI. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check HCCI's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, MEG has a market cap of 792.7M. Regarding current trading prices, SMED is priced at $8.75, while MEG trades at $22.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas MEG's P/E ratio is -157.36. In terms of profitability, SMED's ROE is +0.34%, compared to MEG's ROE of -0.00%. Regarding short-term risk, SMED is less volatile compared to MEG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check MEG's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, HSC has a market cap of 729.6M. Regarding current trading prices, SMED is priced at $8.75, while HSC trades at $9.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas HSC's P/E ratio is -5.08. In terms of profitability, SMED's ROE is +0.34%, compared to HSC's ROE of -0.49%. Regarding short-term risk, SMED is less volatile compared to HSC. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check HSC's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, YDDL has a market cap of 423.8M. Regarding current trading prices, SMED is priced at $8.75, while YDDL trades at $9.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas YDDL's P/E ratio is 64.07. In terms of profitability, SMED's ROE is +0.34%, compared to YDDL's ROE of +0.36%. Regarding short-term risk, SMED is less volatile compared to YDDL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check YDDL's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, PESI has a market cap of 218.4M. Regarding current trading prices, SMED is priced at $8.75, while PESI trades at $12.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas PESI's P/E ratio is -18.43. In terms of profitability, SMED's ROE is +0.34%, compared to PESI's ROE of -0.20%. Regarding short-term risk, SMED is less volatile compared to PESI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check PESI's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, ESGL has a market cap of 136.9M. Regarding current trading prices, SMED is priced at $8.75, while ESGL trades at $3.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas ESGL's P/E ratio is -53.83. In terms of profitability, SMED's ROE is +0.34%, compared to ESGL's ROE of -0.06%. Regarding short-term risk, SMED is less volatile compared to ESGL. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check ESGL's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, LNZA has a market cap of 51.9M. Regarding current trading prices, SMED is priced at $8.75, while LNZA trades at $23.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas LNZA's P/E ratio is -0.61. In terms of profitability, SMED's ROE is +0.34%, compared to LNZA's ROE of +16.96%. Regarding short-term risk, SMED is less volatile compared to LNZA. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check LNZA's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, LICY has a market cap of 29.9M. Regarding current trading prices, SMED is priced at $8.75, while LICY trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas LICY's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to LICY's ROE of +0.03%. Regarding short-term risk, SMED is less volatile compared to LICY. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check LICY's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, JAN has a market cap of 27.1M. Regarding current trading prices, SMED is priced at $8.75, while JAN trades at $2.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas JAN's P/E ratio is -0.51. In terms of profitability, SMED's ROE is +0.34%, compared to JAN's ROE of +0.14%. Regarding short-term risk, SMED is less volatile compared to JAN. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check JAN's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, AMBI has a market cap of 24.4M. Regarding current trading prices, SMED is priced at $8.75, while AMBI trades at $0.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas AMBI's P/E ratio is -44.00. In terms of profitability, SMED's ROE is +0.34%, compared to AMBI's ROE of -0.06%. Regarding short-term risk, SMED is less volatile compared to AMBI. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AMBI's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, QRHC has a market cap of 21.6M. Regarding current trading prices, SMED is priced at $8.75, while QRHC trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas QRHC's P/E ratio is -1.41. In terms of profitability, SMED's ROE is +0.34%, compared to QRHC's ROE of -0.36%. Regarding short-term risk, SMED is less volatile compared to QRHC. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check QRHC's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, CHRA has a market cap of 20.3M. Regarding current trading prices, SMED is priced at $8.75, while CHRA trades at $5.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas CHRA's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to CHRA's ROE of +20.59%. Regarding short-term risk, SMED is more volatile compared to CHRA. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check CHRA's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, ENGS has a market cap of 14.7M. Regarding current trading prices, SMED is priced at $8.75, while ENGS trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas ENGS's P/E ratio is -4.48. In terms of profitability, SMED's ROE is +0.34%, compared to ENGS's ROE of +0.28%. Regarding short-term risk, SMED is less volatile compared to ENGS. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check ENGS's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, AQMS has a market cap of 12.6M. Regarding current trading prices, SMED is priced at $8.75, while AQMS trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas AQMS's P/E ratio is -0.15. In terms of profitability, SMED's ROE is +0.34%, compared to AQMS's ROE of -2.74%. Regarding short-term risk, SMED is less volatile compared to AQMS. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AQMS's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, AWX has a market cap of 10.1M. Regarding current trading prices, SMED is priced at $8.75, while AWX trades at $2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas AWX's P/E ratio is 64.75. In terms of profitability, SMED's ROE is +0.34%, compared to AWX's ROE of +0.00%. Regarding short-term risk, SMED is less volatile compared to AWX. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check AWX's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, CHNR has a market cap of 5.6M. Regarding current trading prices, SMED is priced at $8.75, while CHNR trades at $4.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas CHNR's P/E ratio is -8.94. In terms of profitability, SMED's ROE is +0.34%, compared to CHNR's ROE of -0.00%. Regarding short-term risk, SMED is less volatile compared to CHNR. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CHNR's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, CDTG has a market cap of 4.7M. Regarding current trading prices, SMED is priced at $8.75, while CDTG trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas CDTG's P/E ratio is -3.21. In terms of profitability, SMED's ROE is +0.34%, compared to CDTG's ROE of -0.01%. Regarding short-term risk, SMED is less volatile compared to CDTG. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CDTG's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, GWAV has a market cap of 3M. Regarding current trading prices, SMED is priced at $8.75, while GWAV trades at $3.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas GWAV's P/E ratio is 0.02. In terms of profitability, SMED's ROE is +0.34%, compared to GWAV's ROE of -0.89%. Regarding short-term risk, SMED is less volatile compared to GWAV. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check GWAV's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, DXST has a market cap of 2.1M. Regarding current trading prices, SMED is priced at $8.75, while DXST trades at $3.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas DXST's P/E ratio is -160.50. In terms of profitability, SMED's ROE is +0.34%, compared to DXST's ROE of -0.04%. Regarding short-term risk, SMED is less volatile compared to DXST. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check DXST's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, CVA has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while CVA trades at $20.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas CVA's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to CVA's ROE of -0.08%. Regarding short-term risk, SMED is less volatile compared to CVA. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check CVA's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, ECOL has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while ECOL trades at $47.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas ECOL's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to ECOL's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to ECOL. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check ECOL's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, NES has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while NES trades at $2.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas NES's P/E ratio is -1.32. In terms of profitability, SMED's ROE is +0.34%, compared to NES's ROE of -0.29%. Regarding short-term risk, SMED is less volatile compared to NES. This indicates potentially lower risk in terms of short-term price fluctuations for SMED.Check NES's competition here

SMED plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SMED stands at 0. In comparison, ECOLW has a market cap of 0. Regarding current trading prices, SMED is priced at $8.75, while ECOLW trades at $5.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SMED currently has a P/E ratio of 36.46, whereas ECOLW's P/E ratio is N/A. In terms of profitability, SMED's ROE is +0.34%, compared to ECOLW's ROE of +0.01%. Regarding short-term risk, SMED is more volatile compared to ECOLW. This indicates potentially higher risk in terms of short-term price fluctuations for SMED.Check ECOLW's competition here